3Seve P,Dumontet C.Chemoresistance in non-small cell lung cancer.Curr Med Chem Anticancer Agents,2005,5(1):73-88.
4Seve P,Mackey J,Isaac S,et al.Class Ⅲ beta-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel.Mol Cancer Ther,2005,4(12):2001-2007.
5Wachtersa FM,Wongb LSM,Timensc W,et al.ERCC1,hRad51 and BRCA1 protein expression in relation to tumour response and survival of stage Ⅲ/Ⅳ NSCLC patients treated with chemotherapy.Lung Cancer,2005,50(2):211-219.
6Rosell R,Taron M,Barnadas A,et al.Nucleotide excision repair pathways involved in cisplatin resistance in non-small cell lung cancer.Cancer Control,2003,10 (4):297-305.
7Urano N,Fujiwara Y,Doki Y,et al.Clinical significance of class-Ⅲ beta-tubulin expression and its predictive value for resistance to docetaxel-based chemotherapy in gastric cancer,Int Oncol,2006,28(2):375-381.
8Seve P,Lai R,Ding K,et al.Class Ⅲβ -tubulin expression and benefit from adjuvant Cisplatin/Vinorelbine chemotherapy in operable nonsmall cell lung cancer:Analysis of NCIC JBR.10.Clin Cancer Bes,2007,13(3):994-999.
9Sherpherd FA.Surgical management of small cell lung cancer[M].In:Pass HI.Eds:Lung cancor:principles and practice.2 nd edition.Philadelphia:Lippincott-Raven,2000.967-980.
10Szczesny T J,Szczesna A,Shepherd FA,et al.Surgical treatment of small cell lung cancer[J].Semin Oncol,2003,30:47-56.
